Elevation of Activated Platelet-Dependent Chemokines in Patients With Anti-CD20 Monoclonal Antibody (Rituximab)−Treated Non-Hodgkin's Lymphoma

Abstract

.ocn.ne.jp. This study measured and compared levels of some chemokines in patients with rituximab-treated non-Hodgkin lymphoma because they may participate in the mechanism of efficacy of rituximab in non-Hodgkin lymphoma patients. Monocytic chemotactant protein-1, RANTES (regulated on activation, normally T-cell expressed and secreted), eotaxin, interleukin-8, neutrophil-activating protein-78, stromal cell-derived factor-1, and growth-regulating oncogene-α in patients with rituximab-treated non-Hodgkin lymphoma were measured by enzyme-linked immunosorbent assay. Levels of RANTES were higher in non-Hodgkin lymphoma patients than in controls. Levels of monocytic chemotactant protein-1, RANTES, and neutrophil-activating protein-78 were significantly elevated before and after chemotherapy with rituximab treatment. However, the level of stromal cell-derived factor-1 did not exhibit a significant change. Before to after chemotherapy without rituximab treatment, all chemokine levels did not exhibit significant changes. These findings suggest that activated platelet-dependent chemokines such as RANTES and neutrophil-activating protein-78 may modulate the efficacy of rituximab in antibody-dependent cellular cytotoxity.

Keywords

Rituximab non-Hodgkin's lymphoma chemokine

References

Luster AD Chemokines—chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436-445.

Wong MM , Fish EN Chemokines: attractive mediators of the immune response. Semin Immunol. 2003;15:5-14.

Teruya-Feldstein J. , Tosato G. , Jaffe ES The role of chemokines in Hodgkin's disease . Leukemia Lymphoma. 2000;38:363-371.

Baggiolini M. , Dewald B. , Moser B. Human chemokines: an update. Annu Rev Immunol. 1997;15:675-705.

Rollins BJ , Yoshimura T. , Leonard EJ , Pober JS Cytokine-activated human endothelial cells synthesize and secrete a monochemoattractant, MCP-1/JE. Am J Pathol. 1990; 136:1229-1233.

Colotta F. , Borre A. , Wang JM , et al. Expression of a monocyte chemotactic cytokine by human mononuclear phagocytes. J Immunol. 1992;148:760-765.

Tedla N. , Palladinetti P. , Wakefield D. , Lloyd A. Abundant expression of chemokines in malignant and infective human lymphadenopathies . Cytokine. 1999;11:531-540.

Husson H. , Carideo EG , Cardoso AA , et al. MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol. 2001;115:554-562.

Baggiolini M. , Dewald B. , Moster B. Interleukin-8 and related chemotactic cytokines—CXC and CC chemokine. Adv Immunol. 1994;55:97-179.

10.

Kameyoshi Y. , Dorschner A. , Mallet AI , Christophers E. , Schroder JM Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med. 1992;176:587-592.

11.

Bleul CC , Fuhlbrigge RC , Casasnovas JM , Aiuti A. , Springer TA A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996;184:1101-1109.

12.

Ahuja SK , Murphy PM The CXC chemokines growth-regulated oncogene (GRO)α, GRO β, GRO γ, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem. 1996;271:20545-20550.

13.

Power CA , Clemetson JM , Clemetson KJ , Wells TN Chemokine and hemokine receptor mRNA expression in human platelets. Cytokine. 1995;7:479-482.

14.

Klinger MH , Wilhelm D. , Bubel S. , Sticherling M. , Schroder JM , Kuhnel W. Immunocytochemical localization of the chemokines RANTES and MIP-1 within human platelets and their release during storage. Int Arch Allergy Immunol. 1995;107:541-546.

15.

Landis S. , Murray T. , Bolden S. , Wingo PA Cancer statistics. 1998. CA Cancer J Clin. 1998;48:6-29.

16.

Harris NL , Jaffe ES , Stein H. , et al. Lymphoma classification proposal: Clarification. Blood. 1995;85:857-860.

17.

Anderson KC , Bates MP , Slaughenhoupt BL Pinkus GS , Schlossman SF , Nadler LM Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood. 1984;63:1424-1433.

18.

Einfeld DA , Brown JP , Valentine MA Clark EA , Ledbetter JA Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J. 1988;7:711-717.

19.

Tedder TF , Engel P. CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15:450-454.

20.

Stashenko P. , Nadler LM , Hardy R. , Schlossman SF Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678-1685.

21.

Press OW , Appelbaum F. , Ledbetter JA , et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584-591.

22.

Knox SJ , Goris ML , Trisler K. , et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.

23.

Coiffier B. , Haioun C. , Ketterer N. , et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927 -1932.

24.

McLaughlin P. , Grillo-Lopez A. , Link BK , et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a fourdose treatment program. J Clin Oncol. 1998;16: 2825-2833.

25.

Davis TA , White CA , Grillo-Lopez A. , et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol. 1999;17:185-187.

26.

Shan D. , Ledbetter JA , Press OW Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673-683.

27.

Golay J. , Zaffaroni L. , Vaccari T. , et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900-3908.

28.

Reff ME , Carner K. , Chambers KS , et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445

29.

Christiansen I. , Sundstrom C. , Kalkner KM , et al. Serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) are elevated in advanced stages of non-Hodgkin's lymphomas. Eur J Haematol. 1999;62:202-209.

30.

Bogetto L. , Gabriele E. , Cariati R. , et al. Bidirectional induction of the cognate receptor-ligand α4/VCAM-1 pair defines a novel mechanism of tumor intravasation. Blood . 2000;95: 2397-2406.

31.

Haznedaroglu IC , Benekli M. , Ozcebe O. , et al. Serum L-selectin and P-selectin levels in lymphomas. Haematologica. 2000;30:27-30.

32.

Koch AE , Kunkel SL , Harlow LA , et al. Macrophage inflammatory protein-1: a novel chemokine cytokine for macrophages in rheumatoid arthritis. J Clin Invest. 1994; 93:921-928.

33.

Pattison J. , Nelson PJ , Huie P. , et al. RANTES chemokine expression in cell-mediated transplant rejection of the kidney. Lancet. 1994;343:209-211.

34.

Cocchi F. , DeVico AL , Garzino-Demo A. Arya SK , Gallo RC , Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270:1811-1815.

35.

Holme PA , Muller F. , Solum NO , Brosstad F. , Froland SS , Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J. 1998;12:79-89.

36.

Czuczman MS , Grillo-Lopez AJ , White CA , et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999; 17:268-276

37.

Hainsworth JD , Litchy S. , Burris HA , et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol. 2002;20: 4261-4267.

38.

Howard OM , Gribben JG , Neuberg DS , et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete response are not predictive of progression-free survival. J Clin Oncol. 2002;20: 1288-1294.

39.

Matsushima K. , Larsen CG , DuBois GC , Oppenheim JJ Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989;169:1485-1490.

40.

Cushing SD , Berliner JA , Valente AJ , et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 1990;87:5134-1538.

41.

Schaniel C. , Pardali E. , Sallusto F. , et al. Activated murine B lymphocytes and dendritic cells produce a novel CC chemokine which acts selectively on activated T cells. J Exp Med. 1998;188:451-463.

42.

Loetscher P. , Seitz M. , Clark-Lewis I. , Baggiolini M. , Moser B. Activation of NK cells by CC chemokines. Chemotaxis, Ca 2+ mobilization, and enzyme release. J Immunol. 1996; 156:322-327.

43.

Maghazachi AA , AI-Aoukaty A. , Schall TJ CC chemokines induce the generation of killer cells from CD56+ cells. Eur J Immunol. 1996;26:315-319.

44.

Xu LL , Warren MK , Rose WL Gong W. , Wang JM , et al. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro . J Leukoc Biol. 1996;60:365-371.

45.

Taub DD , Ortaldo JR , Turcovski-Corrales SM , Key ML , Longo DL , Murphy WJ Beta chemokines constimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol. 1996;59:81-89.

46.

Adema GJ , Hartgers F. , Verstraten R. , et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature. 1997;387:713-717.

47.

Kim JJ , Nottingham LK , Sin JI , et al. CD8 positive T cells influence antigen-specific luumune responses through the expression of chemokines. J Clin Invest. 1998;102: 1112-1124.

48.

Appay V. , Dunbar PR , Cerundolo V. , McMichael A. , Czaplewski L. , Rowland-Jones S. RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. Int Immunol. 2000;12: 1173-1182.

49.

Walz A. , Burgener R. , Car B. , Baggiolini M. , Kunkel SL , Strieter RM Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J Exp Med. 1991;174:1355-1362.

50.

Biswas P. , Delfanti F. , Bernasconi S. , et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral mononuclear cells and in the U937 cell line. Blood. 1998;91:258-265.

51.

Winkler U. , Jensen M. , Manzke O. , Schulz H. , Diehl V. , Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood. 1999;94:2217-2224.

52.

Power CA , Furness RB , Brawand C. , Wells TN Cloning of a full-length cDNA encoding the neutrophil-activating peptide ENA-78 from human platelets. Gene. 1994;151: 333-334.

53.

Boehlen F. , Clemetson KJ

Platelet chemokines and their receptors: what is their relevance to platelet storage and transfusion practice?

Transfus Med. 2001;11: 403-417.

54.

Nomura S. , Tandon NN , Nakamura T. , Cone J. , Fukuhara S. , Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis. 2001;158:277-287.

55.

Matsumoto N. , Nomura S. , Kamihata H. , Kimura Y. , Iwasaka T. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost. 2004;91:146-154.

56.

Horsewood P. , Hayward CP , Warkentin TE , Kelton JG Investigation of the mechanisms of monoclonal antibody-induced platelet activation. Blood. 1991;78:1019-126.